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Osteochondromyxoma is an extremely rare bone tumor associated with 1% of Carney complex patients
and constitutes one of its 11 diagnostic criteria. This narrative review of osteochondromyxoma is based
on a search of all references to the topic in PubMed, Web Of Science, SCOPUS, ScienceDirect, and JSTOR
databases. Special attention was focused on case reports, leading to a review encompassing the case
reports to date, as well as related animal model studies. This review covers the current understanding of
osteochondromyxoma, highlighting its variability while providing consensus on the most common
clinical presentation, pathological ﬁndings, and genetic features of this rare bone tumor.
& 2016 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Carney complex (CNC) is a rare, autosomal dominant, geneti-
cally heterogeneous familial multiple endocrine neoplasia and
lentiginosis syndrome that affects a number of organs [1–5]. First
described in 1985 by J. Aidan Carney as the combination of myx-
omas, spotty pigmentation and endocrine overactivity, it has since
been further characterized by osteochrondomyxomas, recurrent
cardiac myxomas (the lethal component of CNC), cutaneous and
bilateral breast myxomas, multiple endocrine neoplasms, psam-
momatous melanotic schwannomas, pigmented mucosal and skin
lesions, large-cell calcifying Sertoli cell tumors, growth hormone–
secreting pituitary adenomas, and breast ductal adenomas [2,6–
10]. Diagnosis is based on the presence of at least two of these
clinical criteria, conﬁrmed by histology or one criterion and either
a ﬁrst-degree family history of CNC or a PRKAR1A mutation
(HGNC:9388) [3,6]. Carney complex (OMIM 160980) is distinct
from Carney triad (OMIM 604287) and Carney-Stratakis syndrome
(OMIM 606864) although all three are related to their eponym,
Professor Emeritus of Pathology, J. Aiden Carney, MD, PhD. The
term Carney complex was designated by Bain, which included
nearly all the prior acronym syndrome patients with LAMB (len-
tigines, atrial myxoma, and blue nevi) and NAME (nevi, atrial
myxoma, myxoid neuroﬁbromas, and ephelides) [11,12]. CNC also
has similarities to other syndromes including Bannayan-Zonana,
Birt-Hogg-Dube, Cowden, and McCune-Albright syndromes [4].
As of 2013, more than 750 cases of Carney complex have beenGmbH. This is an open access art
(T. Golden).reported worldwide [13]. Given this rarity, referral of patients to
centers with expertize in CNC is advised [1]. It is therefore bene-
ﬁcial for all providers to be aware of CNC criteria to identify pa-
tients with possible CNC for further evaluation. The most common
presentation (475% of CNC) which is also a diagnostic criterion of
CNC is spotty pigmented skin lesions which normally appear early
in life [1,12,14,15]. These are most often lentigines and epithelioid
blue nevi (with cafe-au lait spots less classically observed), which
can be found anywhere on the body but are typically on the face,
particularly the vermilion lip borders, eyelids, conjunctiva, and
external ear [9,16,17].
As opposed to the commonly found skin lesions, osteochon-
dromyxoma (osteochondroma containing myxoid elements) is one
of the least common presentations of CNC, yet also one of its 11
clinical diagnostic criteria. Osteochondromyxoma (OMX) of bone is
an extremely rare tumor that is always associated with lentigines
and other unusual disorders, and it has in fact been called “Carney
bone tumor” since it is typically associated with Carney complex
[18]. OMX is the most common CNC bone tumor, affecting about
1% of CNC patients (compared to primary pigmented nodular
adrenocortical disease (PPNAD), the most common endocrine tu-
mor in CNC, found in 60% of CNC patients) [19,20]. OMX originate
from bony cortices and have been observed in the nasal region, as
well as the tibia and radius [5]. OMX is the most recently described
tumor associated with CNC and causes swelling, local inﬂamma-
tion, and discomfort with symptoms depending on its site and size
[19,21]. Via imaging, OMX lesions are considered benign however
a detailed imaging evaluation is recommended for patients with
any CNC ﬁndings because of its potential lethality [2,22]. Although
OMX is a rare manifestation of CNC it is important to identify since
symptoms of skeletal neoplasm are nonspeciﬁc, often leading toicle under the CC BY-NC-ND license
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early childhood are uncommon [23]. As recently as 2006 OMX was
identiﬁed as an “unresolved question” due to a lack of literature on
the topic [24]. This review covers the current understanding of
OMX by characterizing its presentation, pathology, genetics,
management and prognosis.2. Presentation
Osteochondromyxoma can occur at any age, but typically pre-
sents before age 2 and has been reported at birth [1,5,25]. Carney
et al. hypothesize that the tumor itself can be congenital [5].
Though little has been published on the appearance of OMX, it can
be distinguished based on its unique site, symptoms, and radio-
graphic appearance from other craniofacial myxoid bone lesions
(e.g. chondroblastoma, chondromyxoid ﬁbroma, rhabdomyo-
sarcoma, mxyoid chondrosarcoma, and neuroﬁbroma) [26,27].
OMX can occur in any bone but most frequently presents on the
diaphysis of long bones (especially the tibia and radius) as well as
the sinus and nasal bones [2,5,16,21,27–29]. Two cases have re-
ported occlusion of the nasal sinus due to an OMX tumor [5,18]. If
not surrounding vital structures, the mass may go unnoticed until
becoming large in size. Such a case was reported from a tumor
growing on the tibia [5]. Other historical cases, all in the non-
English literature, have reported OMX of the rib, chest wall, and
spine [30–32].
Osteochondromyxoma is characterized as a painless mass with
additional symptoms due to edema and mass effect [5,7,27,29].
One case, for example, involved an infant with a tumor blocking
the nasal turbinate, which led to difﬁculties with breastfeeding [5].
Since OMX is associated with 1% of patients with Carney complex,
other symptoms pertaining to CNC may present, namely cardio-
vascular and endocrine abnormalities along with spotty skin pig-
mentation [28,29,33]. While OMX in young patients is associated
with Carney complex, OMX in adults can occur as an isolated
entity [5]. For example, a 2009 case reported OMX of the maxilla
in a 21-year-old woman who did not exhibit any other Carney
complex criteria [18].
Although OMX is a benign neoplasm it can exhibit locally in-
vasive characteristics similar to that of the most common primary
bone tumor, osteosarcoma [34]. Xenotransplantation of affected
tissue into mice models has shown tumor presence and growth in
as few as eight weeks. Although local growth is rapid and invasive,
it has not been shown to metastasize [25,28]. Although similar to
osteosarcomas, this pattern has also been exhibited by normal
parathyroid cells with orthotopic autotransplantation and xeno-
transplantation in mice models [35,36].
On imaging OMX is well circumscribed and can be destructive
and mineralized, with other aspects of its appearance varying
depending on the tumor’s location [27]. The mass can show ex-
pansion of the affected bone area with mixtures of lucent and
sclerotic regions. On MRI (the most precise imaging method for
symptomatic bone masses), OMX found on the spine presents
with increased T2-weighted signaling. Imaging differential diag-
nosis includes chondromyxoid ﬁbroma, mesenchymal hamartoma,
myxoma, chondrosarcoma with myxoid change, and ﬁ-
brocartilaginous mesenchymoma [7,19].3. Pathological features
Gross pathology may present a well-circumscribed, bony or
cartilaginous, calciﬁed, white mass. The mass tends to change the
nature and matrix of the surrounding bone structures, but it also
may stay conﬁned within the periosteum. The tumor erodessurrounding bone and invades soft tissue. Encapsulation is seldom
present, but has been reported. Histologically, capsules are marked
with 10–15 cell-thick parallel layers; cells contain eosinophilic
cytoplasm and nuclei arranged in rows. However, if no capsule is
appreciated, histological inspection shows no well-deﬁned border
between the tumor and surrounding normal tissue; signs of in-
ﬂammation are seldom noted [5]. Histology consists of sheets with
lobular areas, polymorphic cells, chondroid, osteoid, and hyaline
bands [27]. There is histological similarity between OMX and bi-
zarre parosteal osteochondromatous proliferation (BPOP, also
known by its eponym Nora's lesion, ﬁrst reported in 1983), an-
other rare, locally aggressive, benign condition; however, on H&E
OMX lacks the blue staining of immature bony trabeculae found
with BPOP [37,38].
Light microscopy yields varying ﬁndings. However, the tumor is
usually composed of a mixture of mesenchymal cells, basophilic
myxoid material, and mucopolysaccharide ground substance. The
degree of cellularity is inversely proportional to the amount of
myxoid material and matrix [5,25]. Osteoid and bone, immature
and mature cartilage, hyaline ﬁbrous bands and nodules, and
collagen ﬁbers are also scattered within the tumor, varying
throughout the tissue sample. While the cells are usually orga-
nized in sheets in either well-deﬁned or disorganized microlobular
or macrolobular patterns, there are occasional ill-deﬁned cell
whorls. Larger lobules are conﬁned by a peripheral cellular border,
which also contain multiple small, sinusoidal blood vessels. With
accumulation of the matrix, the sheets of cells tend to undergo
dissociation from small and irregular shaped cell aggregates to
tenuously-linked strands and cords that form a reticular network
of cells [5]. Atypical cellularity and necrosis are seldom seen
[4,5,25].
Most cells found in microscopy are polygonal, stellate, and bi-
polar. Cytoplasmic vacuolization with occasional inclusion bodies
are common around myxochondroid areas. Chondroblast-like cells
and osteoblast-like cells are found throughout the tissue; both
cells are involved with osteoid development. Small foci containing
adipocytes are found throughout samples. The nuclei of cells are
rarely atypical. They present as well preserved, chromatic, and
vesicular with small, discernable nucleoli [5].
Histochemically, the cytoplasm of tumor cells stain periodic
acid-Schiff (PAS) positive. The positivity is strongest where matrix
is minimal, as suggested by the inverse proportion of cell to ma-
trix. Cell cytoplasm and matrix are positive for colloidal iron. Tu-
mor cells stain positive for vimentin and occasionally S-100 pro-
tein. Collagen II staining is focal and moderate while collagen IV
staining is minimal. Movat pentachrome staining helps discern the
tumor components: myxomatous (faint blue), cartilaginous (blue,
green, and olive), hyaline (yellow), and osseous (yellow, scarlet,
and brick red) [5].4. Genetics
The American College of Medical Genetics and Genomics as
well as the National Society of Genetic Counselors recommend
genetic counseling for cancer predisposition when a patient with
Carney complex presents with OMX [39]. So far two loci have been
associated with Carney complex: one in chromosome 2 and the
other in chromosome 17; and in inherited cases, Carney complex is
an autosomal-dominant trait with almost 100% penetrance
[1,10,33,40]. It is most often associated with mutations (most often
deletions) in 17q24 in the gene PRKAR1A (protein kinase cAMP-
dependent type I regulatory subunit alpha, HGNC:9388), also
known as CNC1, as well as in 2q31 in the gene PDE11A (phos-
phodiesterase 11A, HGNC:8773), with ongoing research to identify
other genes [9,40–42].
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dromyxoma [1,29]. It is believed to arise from distorted me-
senchymal stem cells designated to become osteoblasts [4,25]. In
particular, the mutation is seen to cause a hyperstimulation of
protein kinase A (PKA) when elevated levels of cyclic AMP (cAMP)
are present within the cell [4]. Carney complex has a mutation
affecting the sensitivity and function of the alpha-1 subunit of
protein PKA toward cAMP [1,33]. Parathyroid hormone (PTH) sti-
mulates osteoblasts via the PKA/cAMP pathway. Since the genetic
mutation causes hyperresponsiveness to elevated levels of cAMP, it
is believed that PTH serves as a chronic stimulator for tumor
growth [43,44].
In mice experiments of the Prkar1a mutation (MGI:104878) seen
in Carny complex, Kirschner et al. found that mice sustaining the
Prkar1aΔ2/þ mutation exhibited multiple tumors on the tail that
were described as similar to OMX human lesions. The tumors arose
in 50% of mice with the mutation in eight months and in 80% at one
year. Radiographs showed radiolucent lesions in the vicinity of the
tailbone [4]. This radiographic appearance mimics that of OMX in
humans; the tumor replaces the trabecular network seen in normal
bone into myxoid and gelatinous features [5]. Histologically, the
tumors of the mice tails showed a mixture of spindled, polygonal,
stellate, and inﬂammatory cells within a background of matrix.
These characteristics are similarly described in osteochondromyx-
oma lesions found in Carney complex patients [4,5].
Microarray analysis of mutated osteoblasts shows about 250
altered transcripts. One of them is Runx2 (Runt-related tran-
scription factor-2, MGI:99829), a gene that is claimed to be a major
control for osteoblast differentiation [25,45,46]. Chromatin im-
munoprecipitation and luciferase assays also show repression of
DNA binding and functioning of Runx2 at its target genes. There
are also reductions in Runx2-cooperating transcription factors
such as Foxo1 (forkhead box O1, MGI:1890077) and Atf4 (activat-
ing transcription factor 4, MGI:88096) [46]. The osteoblasts af-
fected by the Prkar1a mutation also display suppressed bone no-
dule formation in addition to markers osteocalcin and osteopontin
[25,46]. Downregulation of other markers includes Il6st (inter-
leukin-6 signal transducer, MGI:96560), a gene that codes for
gp130 subunit of the IL-6 receptor [47]. However, the transcript
with the most signiﬁcant drop is CILP (cartilage intermediate layer
protein, MGI:2444507), a structural protein that plays a role in
matrix composition and bone formation [48,49].
One gene noted to be upregulated via evidence of increased
mRNA and protein levels is Wnt5a (Wingless-Type MMTV In-
tegration Site Family, Member 5A, MGI:98958). Wnt signaling is
known to aid in bone formation by inﬂuencing osteoblasts [25]. A
link between elevated levels of Wnt and adrenal tumors of Carney
complex patients has been reported [42]. This may signify a pos-
sible link between Wnt mutations and tumors found within Car-
ney complex patients [25].
While the lesions exhibited by the experimental mice are most
similar to patients with Carney complex, the features are also si-
milar to those seen in McCune-Albright syndrome (MAS) [4,25,50–
53]. Similarities between the two are not unexpected as both
syndromes arise from mutations affecting the cAMP/PKA signaling
pathway within osteoblasts [4]. MAS has the mutation in the sti-
mulatory G protein, a subunit (encoded GNAS1, MGI:95777) which
also hyperstimulated cAMP/PKA signaling [54,55]. The dysplastic
bone lesions seen in both syndromes are believed to be due to
osteoblast dysregulation, particularly in terms of differentiation
and proliferation controlled by PKA signals [4]. Similar to Schwann
cells, osteoblasts are reliant on the physiological responses to
cAMP and PKA in order to proliferate and mature [56,57]. This may
further be supported by the presence of Schwann cell abnormal-
ities, namely psammomatous melanotic schwannoma, in Carney
complex patients [1,33]. Although clinical presentation and grosspathology are similar in the two syndromes, histological appear-
ances differ. The mice exhibiting the Prkar1a Δ2/þ mutation con-
tained hypocellular and immensely myxoid matrixes. The bony
trabeculae also were rimmed with normal-appearing osteoblasts.
These ﬁndings are similar to Carney complex patients with os-
teochondromyxoma. Polyostotic ﬁbrous dysplasia in MAS contain
greater cellularity and lack a normal-osteoblast comprised rim
[4,50].5. Management and prognosis
With complete excision OMX has a good prognosis (unlike
several other bone myxoid lesions, e.g., chondromyxoid ﬁbroma
and rhabdomyosarcoma) [27]. In fact, complete excision of OMX
can be curative, however local recurrence is very common with
incomplete resection [5,27,34]. Disease recurrence is therefore
more likely at sites where complete resection is difﬁcult [28]. Since
metastasis have never been suggested, recognition and complete
excision are key to a good prognosis [4,5,25].Conﬂict of interest statement
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